Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | FABP7 | O15540 | 1/20 | 0.35 |
| ▸ | FABP3 | P05413 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27085618 | 1.00 | TSHR (0.40) | TSHRPOLBCYP2D6SLC6A4SLC6A3 | |
| SCHEMBL27085628 | 1.00 | TSHR (0.40) | TSHRPOLBCYP2D6SLC6A4SLC6A3 | |
| SCHEMBL16808481 | 1.00 | TSHR (0.40) | TSHRPOLBCYP2D6SLC6A4SLC6A3 | |
| SCHEMBL18186731 | 0.85 | TSHR (0.44) | TSHRPOLBCYP2D6SLC6A4SLC6A3 | |
| SCHEMBL28364992 | 0.85 | TSHR (0.44) | TSHRPOLBCYP2D6SLC6A4SLC6A3 | |
| SCHEMBL16808624 | 0.85 | TSHR (0.44) | TSHRPOLBCYP2D6SLC6A4SLC6A3 | |
| SCHEMBL28365208 | 0.85 | TSHR (0.44) | TSHRPOLBCYP2D6SLC6A4SLC6A3 | |
| SCHEMBL16808494 | 0.85 | TSHR (0.44) | TSHRPOLBCYP2D6SLC6A4SLC6A3 | |
| SCHEMBL29015071 | 0.85 | MAPT (0.39) | TSHRPOLBCYP2D6SLC6A4SLC6A3 | |
| SCHEMBL15539970 | 0.85 | MAPT (0.39) | TSHRPOLBCYP2D6SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-02-13 | — | — | US | disclosed |
| EP-4211125-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-19 | — | — | EP | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| WO-2022054987-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-03-17 | — | — | WO | disclosed |
| US-9937145-B2 | Sulfamate derivative compound for use in preventing or treating epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-04-10 | — | — | US | disclosed |
| US-9937145-B2 | Sulfamate derivative compound for use in preventing or treating epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-04-10 | — | — | US | disclosed |
| US-9834535-B2 | Sulfamate derivative compounds for use in treating or alleviating pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| US-9834535-B2 | Sulfamate derivative compounds for use in treating or alleviating pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| EP-2861571-B1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO LTD (KR) | 2017-05-03 | — | — | EP | disclosed |
| US-20160318894-A1 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-11-03 | — | — | US | disclosed |
| US-20160310461-A1 | Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-10-27 | — | — | US | disclosed |
| US-20160310461-A1 | Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-10-27 | — | — | US | disclosed |
| US-9221783-B2 | Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-12-29 | — | — | US | disclosed |
| US-9221783-B2 | Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-12-29 | — | — | US | disclosed |
| US-20150266848-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-09-24 | — | — | US | disclosed |
| US-20150266848-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-09-24 | — | — | US | disclosed |
| WO-2015088273-A9 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO-PHARM SOLUTIONS, CO., LTD. (KR) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015088273-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO-PHARM SOLUTIONS, CO., LTD. (KR) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015088271-A1 | SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY | BIO-PHARM SOLUTIONS, CO., LTD. (KR) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318894-A1 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | SULT2A1, STS, SULT1A1 | TSHR 4413/4885POLB 4662/4885CYP2D6 1247/4885 |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | SLC6A4, SLC6A3, SLC6A2 | TSHR 2322/4885POLB 4414/4885CYP2D6 1530/4885 |
| US-20150266848-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | MYLK, MUSK, MYLK2 | TSHR 2872/4885POLB 4550/4885CYP2D6 2957/4885 |
| US-20160310461-A1 | Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy | STS, SULT2A1, GRIK5 | TSHR 4659/4885POLB 4592/4885CYP2D6 670/4885 |
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | SLC6A4, SLC6A3, SLC6A2 | TSHR 2322/4885POLB 4414/4885CYP2D6 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.